Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$144.95 - $152.29 $2.51 Million - $2.64 Million
-17,305 Reduced 86.51%
2,699 $408,000
Q2 2022

Aug 15, 2022

BUY
$83.14 - $145.99 $1.66 Million - $2.92 Million
20,004 New
20,004 $2.91 Million
Q2 2021

Aug 16, 2021

SELL
$65.78 - $105.02 $15,260 - $24,364
-232 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$64.07 - $91.75 $1.56 Million - $2.23 Million
-24,330 Reduced 99.06%
232 $16,000
Q4 2020

Feb 16, 2021

SELL
$65.07 - $98.24 $63,638 - $96,078
-978 Reduced 3.83%
24,562 $2.11 Million
Q3 2020

Nov 13, 2020

SELL
$59.04 - $77.95 $5.19 Million - $6.86 Million
-87,969 Reduced 77.5%
25,540 $1.66 Million
Q2 2020

Aug 14, 2020

BUY
$29.01 - $74.23 $3.27 Million - $8.37 Million
112,697 Added 13878.94%
113,509 $8.3 Million
Q1 2020

May 15, 2020

SELL
$27.51 - $57.29 $561,121 - $1.17 Million
-20,397 Reduced 96.17%
812 $28,000
Q2 2019

Aug 14, 2019

SELL
$39.79 - $67.01 $1.3 Million - $2.19 Million
-32,640 Reduced 60.61%
21,209 $929,000
Q1 2019

May 15, 2019

BUY
$34.52 - $53.29 $1.86 Million - $2.87 Million
53,830 Added 283315.78%
53,849 $2.77 Million
Q4 2018

Feb 14, 2019

BUY
$29.75 - $42.9 $565 - $815
19 New
19 $1,000
Q2 2018

Aug 14, 2018

SELL
$23.62 - $42.29 $298,863 - $535,095
-12,653 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$22.49 - $34.56 $248,671 - $382,129
11,057 Added 692.79%
12,653 $326,000
Q4 2017

Feb 14, 2018

BUY
$20.44 - $35.56 $32,622 - $56,753
1,596
1,596 $43,000

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.8B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Parallax Volatility Advisers, L.P. Portfolio

Follow Parallax Volatility Advisers, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.